Brokerages expect Veru Inc. (NASDAQ:VERU – Get Rating) to post sales of $18.04 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Veru’s earnings. The highest sales estimate is $18.90 million and the lowest is $17.10 million. Veru posted sales of $17.66 million in the same quarter last year, which suggests a positive year-over-year growth rate of 2.2%. The business is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Veru will report full year sales of $75.51 million for the current year, with estimates ranging from $64.80 million to $100.00 million. For the next fiscal year, analysts forecast that the business will post sales of $95.08 million, with estimates ranging from $75.02 million to $126.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Veru.
Veru (NASDAQ:VERU – Get Rating) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Veru had a negative return on equity of 18.15% and a negative net margin of 45.56%. During the same period in the previous year, the company earned ($0.04) EPS.
Hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its position in shares of Veru by 833.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,600 shares of the company’s stock worth $49,000 after buying an additional 5,000 shares in the last quarter. Ensign Peak Advisors Inc bought a new stake in Veru during the 4th quarter valued at $51,000. Josh Arnold Investment Consultant LLC bought a new stake in Veru during the 4th quarter valued at $59,000. Bridgefront Capital LLC purchased a new position in shares of Veru during the 4th quarter valued at $63,000. Finally, XTX Topco Ltd grew its position in shares of Veru by 18.7% during the 1st quarter. XTX Topco Ltd now owns 14,426 shares of the company’s stock valued at $70,000 after purchasing an additional 2,270 shares in the last quarter. 29.11% of the stock is owned by hedge funds and other institutional investors.
Veru stock opened at $13.00 on Monday. The business has a 50 day simple moving average of $8.17 and a 200 day simple moving average of $7.04. Veru has a one year low of $4.34 and a one year high of $17.50. The company has a market capitalization of $1.04 billion, a PE ratio of -38.23 and a beta of -0.57.
Veru Company Profile (Get Rating)
Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.
- Get a free copy of the StockNews.com research report on Veru (VERU)
- Volatile Times Are When AbbVie Shines the Brightest
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.